Next Generation Tumor Targets
Targeting novel tumor antigens for greater specificity and multifunctional anti-tumor activity.
A New Chapter
Synergy Immunotherapeutics (IMT), is dedicated to developing highly effective cancer treatments for patients in need.
Solid tumor therapeutics frequently fail to adequately address the physical and immunosuppressive barriers created by cells within the tumor microenvironment (TME). Maximally effective higher dosing is often not possible due to severe dose-limiting toxicities. Tumor heterogeneity can allow tumor subpopulations to escape antigen specific immunotherapeutics and progress as drug resistant tumors.
A discovery platform identifies novel tumor and protumor TME target cell antigens that enable the generation of immunotherapeutics that can disrupt the TME physical and immunosuppressive barriers. The target antigens appear to be restricted to tumor and critical protumor TME cells allowing for more effective on-target on-tumor killing without severe dose-limiting toxicities. Several target antigens are expressed on a single tumor cell and certain antigens appear to be expressed on all tumor cells and function in their survival; decreasing the risk of drug resistance. Immunotherapeutics targeting these novel stress/survival tumor antigens (sTA) therefore can address the most pressing clinical barriers for solid tumor treatment. Antibodies specific for sTA capture potential biomarkers from cancer patient blood.
Emerging Therapeutic Solutions
Novel sTA have been effectively targeted with monospecific antibodies, antibody drug conjugates (ADCs), T cell engagers (TCE) and with innovative multispecific recombinant antibodies and proteins. Given the properties of sTA, there is high potential for a novel adjuvant or stand-alone therapeutics and for synergy with certain approved therapeutics to kill tumor and certain critical protumor TME cells. sTA specific immunotherapeutics can induce or revitalize an anti-tumor immune response. AI is integrated to accelerate and enhance development from discovery to investigative new drug.
